| 1 |
al-Moagel, M.A., Evans, D.G., Abdulghani, M.E., Adam, E., Evans, D.J.Jr., Malaty, H.M. and Graham, D.Y. (1990) Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. American Journal of Gastroenterology, v.85, p.944-948.
|
| 2 |
Basu, P.P., Rayapudi, K., Pacana, T., Shah, N.J., Krishnaswamy, N. and Flynn, M. (2011) A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. American Journal of Gastroenterology, v.106, p.1970-1975.
DOI
|
| 3 |
Brenciaglia, M.I., Fornara, A.M., Scaltrito, M.M., Braga, P.C. and Dubini, F. (1996) Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. Journal of Chemotherapy, v.8, p.52-54.
DOI
|
| 4 |
Gasbarrini, A., Franceschi, F., Armuzzi, A., Ojetti, V., Candelli, M., Torre, E.S., De Lorenzo, A., Anti, M., Pretolani, S. and Gasbarrini, G. (1999) Extradigestive manifestations of Helicobacter pylori gastric infection. Gut, v.45 p.I9-I12.
DOI
|
| 5 |
Irie, Y., Tateda, K., Matsumoto, T., Miyazaki, S. and Yamaguchi, K. (1997) Antibiotic MICs and short timekilling against Helicobacter pylori: therapeutic potential of kanamycin. Journal of Antimicrobial Chemotherapy, v.40, p.235-240.
DOI
|
| 6 |
Kim, J.D. and Kang, Y.G. (2012), 2012 National Health Insurance Statistical Yearbook, National Health Insurance Corporation, Health Insurance Review & Assessment Service.
|
| 7 |
Kim, J.M., Kim, J.S., Jung, H.C., Kim, N., Kim, Y.J., and Song, I.S. (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrobial Agents and Chemotherapy, v.48, p.4843-4847.
DOI
|
| 8 |
Kim, S.G., Jung, H.K., and Lee, H.L. (2013) Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean Journal of Gastroenterology, v.13, n.62, p.3-26.
|
| 9 |
Klein, P.D., Graham, D.Y., Gaillour, A., Opekun, A.R. and Smith, E.O. (1991) Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. The Lancet, v.337, p.1503-1506.
DOI
|
| 10 |
Lee, J.W., Kim, N., Kim, J.M., Nam, R. H., Chang, H., Kim, J.Y., Shin, C.M., Park, Y.S., Lee, D.H. and Jung, H.C. (2013) Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter, v.18, p.206-214.
DOI
ScienceOn
|
| 11 |
NIH Consensus Conference. (1994) H. pylori in peptic ulcer disease. NIH Consensus development panel on Helicobacter pylori in peptic ulcer disease. Journal of the American Medical Association, v.272, p.65-69.
DOI
ScienceOn
|
| 12 |
Lee, J.Y. and Kim, N.Y. (2014) Future trends of Helicobacter pylori eradication therapy in Korea. Korean Journal of Gastroenterology, v.14, n.63, p.158-170.
|
| 13 |
Lee, J.Y., Kim, N., Kim, M.S., Choi, Y.J., Lee, J.W., Yoon, H., Shin, C.M., Park, Y.S., Lee, D.H. and Jung, H.C. (2014) Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Digestive Diseases and Sciences, v.59, n.6, p.1235-1243.
DOI
|
| 14 |
Li, Z., Chang, P.H., Jean, J.S., Jiang, W.T. and Wang, C.J. (2010) Interaction between tetracycline and smectite in aqueous solution. Journal of Colloid and Interface Science, v.341, p.311-319.
DOI
|
| 15 |
Nishizawa, T., Suzuki, H., Suzuki, M., Takahashi, M. and Hibi, T. (2012) Proton pump inhibitor-amoxicillinclarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. Journal of Clinical Biochemistry and Nutrition, v.51, p.114-116.
DOI
|
| 16 |
Oh, H.S., Lee, D.H., Seo, J.Y., Cho, Y.R., Kim, N., Hwang, J.H., Park, Y.S., Lee, S.H., Shin, C.M., Cho, H.J., Jung, H.C. and Song, I.S. (2012) Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. Journal of Gastroenterology and Hepatology, v.27, p.504-509.
DOI
ScienceOn
|
| 17 |
Park, C.S., Lee, S.M., Park, C.H., Koh, H.R., Jun, C.H., Park, S.Y., Lee, W.S., Joo, Y.E., Kim, H.S., Choi, S.K. and Rew, J.S. (2014) Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. American Journal of Gastroenterology, v.109, p.1595-1602.
DOI
|
| 18 |
Suerbaum, S. and Michetti, P. (2002) Helicobacter pylori infection, New England. Journal of Medicine, v.347, p.1175-1186
|
| 19 |
Rimbara, E., Fischbach, L.A. and Graham, D.Y. (2011) Optimal therapy for Helicobacter pylori infections. Nature Reviews Gastroenterology and Hepatology, v.8, p.79-88.
DOI
|
| 20 |
Shiota, S., Murakawi, K., Suzuki, R., Fujioka, T. and Yamaoka, Y. (2013) Helicobacter pylori infection in Japan. Expert Review of Gastroenterology and Hepatology, v.7 p.35-40.
DOI
ScienceOn
|
| 21 |
van der Voort, P.H.J., van der Hulst, R.W.M., Zandstra, D.F., van der Ende, A., Geraedts, A.A.M. and Tytgat, G.N.J. (2000) In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract. Journal of Antimicrobial Chemotherapy, v.46, p.803-805.
DOI
|
| 22 |
Warren, J.R. and Marshall, B.J. (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. The Lancet, v.321, n.8336, p.1273-1275.
DOI
|
| 23 |
World Gastroenterology Organisation global guideline. (2011): Helicobacter pylori in developing countries. Journal of Digestive Diseases, v.12, p.319-326.
DOI
|
webmaster
